Omeros Corp
NASDAQ:OMER
Intrinsic Value
Omeros Corp. operates as a biopharmaceutical company. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of OMER.
Omeros Corp's market capitalization is 188.9m USD.
OMER stock price is 3.09 USD.
OMER.
OMER. Open DCF Valuation
OMER. Open Relative Valuation
OMER has upside potential of 321% compared to the average analyst price target.
Open Wall St Estimates
OMER has positive Net Debt. This means that the company has more debt (330m USD) than cash and short-term investments (172m USD).
OMER's long-term liabilties (403m USD) exceed its long-term assets (378m USD).
OMER's ROE (Return on Equity) has significantly decreased in the last 3 years from 81% to -388%.
OMER's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from -260% to -56%, and is approaching profitability.
OMER has negative Operating Income for the last twelve months.
OMER has negative Net Income for the last twelve months.
OMER's ROE (Return on Equity) for the past 12 months is negative and is equal to -388%.
OMER's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -56%.
OMER has positive Free Cash Flow for the last twelve months.
OMER has negative three-year average ROE (Return on Equity): -88%. The company is not efficient at transforming stockholders' equity into net income.
OMER has negative three-year average ROIC (Return on Invested Capital): -159%. The company is not efficient at using invested capital to generate operating income.
OMER's short-term assets (218m USD) exceed its short-term liabilties (53m USD).
OMER's D/E (Debt to Equity) is very low and is equal to -13.2.
OMER's Altman Z-Score is very low and is equal to -3.95.
OMER doesn't generate enough operating income (-165m USD) to safely cover interest payments on its debt (30m USD).
Fundamental Analysis
Omeros Corp
Balance Sheet Decomposition
Omeros Corp
| Current Assets | 217.9m |
| Cash & Short-Term Investments | 171.8m |
| Receivables | 37.5m |
| Other Current Assets | 8.6m |
| Non-Current Assets | 160.4m |
| PP&E | 20.6m |
| Other Non-Current Assets | 139.8m |
| Current Liabilities | 53.3m |
| Accounts Payable | 7.7m |
| Accrued Liabilities | 37m |
| Other Current Liabilities | 8.6m |
| Non-Current Liabilities | 349.9m |
| Long-Term Debt | 329.7m |
| Other Non-Current Liabilities | 20.2m |
Earnings Waterfall
Omeros Corp
|
Revenue
|
0
USD
|
|
Operating Expenses
|
-164.5m
USD
|
|
Operating Income
|
-164.5m
USD
|
|
Other Expenses
|
46.7m
USD
|
|
Net Income
|
-117.8m
USD
|
Free Cash Flow Analysis
Omeros Corp
What is Free Cash Flow?
OMER Profitability Score
Profitability Due Diligence
Omeros Corp's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
Score
Omeros Corp's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
OMER Solvency Score
Solvency Due Diligence
Omeros Corp's solvency score is 42/100. The higher the solvency score, the more solvent the company is.
Score
Omeros Corp's solvency score is 42/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
OMER Price Targets Summary
Omeros Corp
According to Wall Street analysts, the average 1-year price target for
OMER
is 13 USD
.
Ownership
OMER Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
OMER Price
Omeros Corp
| Average Annual Return | -34.49% |
| Standard Deviation of Annual Returns | 31.26% |
| Max Drawdown | -95% |
| Market Capitalization | 188.9m USD |
| Shares Outstanding | 62 870 000 |
| Percentage of Shares Shorted | 23.98% |
Company Profile
Omeros Corp
Country
Industry
Market Cap
Dividend Yield
Description
Omeros Corp. operates as a biopharmaceutical company. The company is headquartered in Seattle, Washington and currently employs 213 full-time employees. The company went IPO on 2009-10-08. The firm is focused on discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting inflammation, immunologic diseases and cancers. The Company’s lead MASP-2 inhibitor narsoplimab targets the lectin pathway of complement and is the subject of a biologics license application for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Narsoplimab is also in multiple late-stage clinical development programs focused on other complement-mediated disorders, including IgA nephropathy, atypical hemolytic uremic syndrome and coronavirus (COVID-19). OMS906, the Company’s inhibitor of MASP-3, the alternative pathway of complement, is in a Phase 1 clinical trial.
You don't have any saved screeners yet
